학술논문
P062 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB OR COMBINATION THERAPY WITH ORIGINATOR INFLIXIMAB AND IMMUNOMODULATORS SIGNIFICANTLY INCREASES RISK FOR SERIOUS ADVERSE EVENTS IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE
Document Type
Abstract
Source
In Gastroenterology February 2019 156(3) Supplement:S42-S43
Subject
Language
ISSN
0016-5085